EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   2.1.1.80 | Breast Neoplasms |
32367460 |
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
3
3
4 |
| 2.1.1.80 | Carcinoma |
26813693 |
Characterization of the Enzymatic Activity of SETDB1 and Its 1:1 Complex with ATF7IP. |
causal interaction
therapeutic application
unassigned |
3
1
0 |
| 2.1.1.80 | Carcinoma |
30012565 |
Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance. |
diagnostic usage
therapeutic application
unassigned |
3
1
0 |
| 2.1.1.80 | Carcinoma, Hepatocellular |
30332648 |
PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
1
4
1
4 |
| 2.1.1.80 | Cholestasis |
25013773 |
Lobe-specific heterogeneity in asymmetric dimethylarginine and matrix metalloproteinase levels in a rat model of obstructive cholestasis. |
causal interaction
ongoing research
unassigned |
2
4
0 |
| 2.1.1.80 | Choline Deficiency |
6163476 |
The effects of ethionine administration and choline deficiency on protein carboxymethylase activity in mouse pancreas. |
causal interaction
ongoing research
therapeutic application
unassigned |
3
3
1
0 |
| 2.1.1.80 | Diabetes Insipidus |
6864219 |
High-protein carboxymethylase activity and low endogenous methyl acceptor proteins in posterior pituitary lobe of rats lacking neurophysin-vasopressin (Brattleboro rats). |
ongoing research
unassigned |
2
0 |
| 2.1.1.80 | Leukemia |
24993360 |
DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. |
diagnostic usage
therapeutic application
unassigned |
1
4
0 |
| 2.1.1.80 | Leukemia |
28428443 |
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in MLL-Rearranged Leukemia. |
causal interaction
therapeutic application
unassigned |
3
3
0 |
| 2.1.1.80 | Lymphoma |
26005520 |
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity. |
causal interaction
therapeutic application
unassigned |
4
4
0 |
